Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence its...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

AI-Accelerated Structure Elucidation of Boavistamides A-C, Cyclic Depsipeptides from a Marine Filamentous Cyanobacterium Collected in Cabo Verde.

bioRxiv : the preprint server for biology·2026
Same author

AI-Accelerated Structure Elucidation of Boavistamides A<b>-</b>C, Cyclic Depsipeptides from a Marine Filamentous Cyanobacterium Collected in Cabo Verde.

Journal of natural products·2026
Same author

Development of a Lysine-Reactive Targeted Covalent Inhibitor for the P300/CBP-Associated Factor Bromodomain Through Structure-Based Design.

ChemMedChem·2026
Same author

Estrogen deficiency induces pelvic floor muscle atrophy via ERα/GLUT4 pathway.

PloS one·2026
Same author

Rethinking the role of synergy calculations in the next century of drug combination discovery.

Med (New York, N.Y.)·2026
Same author

BRD4 recruitment desilences transcription without erasure or depletion of repressive chromatin.

bioRxiv : the preprint server for biology·2026

Related Experiment Video

Updated: Jun 20, 2026

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis
09:57

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis

Published on: April 5, 2017

Structure-guided development of selective TbcatB inhibitors.

Jeremy P Mallari1, Anang A Shelat, Aaron Kosinski

  • 1Graduate Program in Chemistry and Chemical Biology, University of California, San Francisco, California 94143-2280, USA.

Journal of Medicinal Chemistry
|September 23, 2009
PubMed
Summary

We developed specific inhibitors for the trypanosomal cathepsin TbcatB, a key target for parasite survival. This research validates TbcatB as a drug target and shows potent, selective inhibition is achievable.

More Related Videos

A Microscopic Phenotypic Assay for the Quantification of Intracellular Mycobacteria Adapted for High-throughput/High-content Screening
15:28

A Microscopic Phenotypic Assay for the Quantification of Intracellular Mycobacteria Adapted for High-throughput/High-content Screening

Published on: January 17, 2014

Related Experiment Videos

Last Updated: Jun 20, 2026

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis
09:57

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis

Published on: April 5, 2017

A Microscopic Phenotypic Assay for the Quantification of Intracellular Mycobacteria Adapted for High-throughput/High-content Screening
15:28

A Microscopic Phenotypic Assay for the Quantification of Intracellular Mycobacteria Adapted for High-throughput/High-content Screening

Published on: January 17, 2014

Area of Science:

  • Parasitology
  • Drug Discovery
  • Structural Biology

Background:

  • Trypanosoma brucei causes human African trypanosomiasis.
  • The trypanosomal cathepsin TbcatB is crucial for parasite survival.
  • TbcatB is a potential therapeutic target for treating trypanosomiasis.

Purpose of the Study:

  • To develop potent and selective inhibitors of TbcatB.
  • To validate TbcatB as a druggable target.
  • To achieve specificity against related human and trypanosomal cathepsins.

Main Methods:

  • Structure-guided drug design of TbcatB inhibitors.
  • Enzymatic assays to determine inhibitor potency.
  • In vitro testing for trypanocidal activity and cytotoxicity.

Main Results:

  • Successful development of TbcatB inhibitors with high specificity.
  • Demonstrated potent inhibition of TbcatB enzymatic activity.
  • Confirmed trypanocidal activity with minimal cytotoxicity.

Conclusions:

  • TbcatB is a validated drug target for trypanosomiasis.
  • Selective inhibition of TbcatB is feasible.
  • Developed inhibitors offer a promising starting point for new anti-trypanosomal therapies.